Tissue oxygenation modulation

Tissue oxygenation modulation is a physiological and therapeutic process rather than a single molecular target. It encompasses the regulation of oxygen delivery and utilization within tissues through the coordination of hemoglobin oxygen affinity, microvascular blood flow, and the cellular response to hypoxia [1, 2]. Key therapeutic strategies include shifting the hemoglobin-oxygen dissociation curve (ODC) using allosteric modifiers like efaproxiral or voxelotor, and stabilizing hypoxia-inducible factors (HIF) through the inhibition of prolyl hydroxylase enzymes [3, 4]. Recent research has highlighted the role of S-nitrosohemoglobin (SNO-Hb) as a critical mediator that senses low oxygen levels and releases nitric oxide to induce local vasodilation, thereby matching blood flow to oxygen demand [1, 2]. This multidisciplinary area of drug development is vital for treating conditions characterized by inadequate tissue perfusion, such as peripheral arterial disease, sickle cell disease, and chronic wounds [2, 15].

Other names

Modulation of tissue oxygenationOxygen delivery modulationHemoglobin-oxygen dissociation curve modulationTissue pO2 modulationMicrovascular blood flow autoregulation

Tissue oxygenation is modulated through several molecular mechanisms: allosteric modification of hemoglobin to shift the oxygen dissociation curve (ODC), stabilization of hypoxia-inducible factors (HIF) via prolyl hydroxylase inhibition, and pharmacological enhancement of S-nitrosohemoglobin (SNO-Hb) to trigger microvascular vasodilation in hypoxic regions.